Error message

  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
  • Failed to authorize with Brightcove
News | May 13, 2015

Cancer Targeted Technology Receives $2 Million Grant for PET Prostate Imaging Trials

New PET biomarker designed to bond with prostate-specific membrane antigen on prostate cancer cells

May 13, 2015 — Cancer Targeted Technology (CTT), announced that it was awarded a NIH two-year, $2 million Small Business Innovation Research (SBIR) grant. The funds will be used to develop a new agent that will help diagnose and monitor metastatic prostate cancer.

CTT1057 — a positron emission tomography (PET) imaging agent discovered by Cliff Berkman, Ph.D., professor of chemistry at Washington State University and CTT chief scientific officer — may be well-suited for imaging the location of cancer metastases that have escaped the prostate gland. Unlike other prostate cancer targeting agents, CTT1057 is a small molecule that homes and binds irreversibly to prostate-specific membrane antigen (PSMA) that is overexpressed on prostate cancer.

Berkman commented, “Our team has spent several years carefully developing and optimizing CTT1057; as the lead scientist on this program I am excited that this SBIR grant will allow CTT to translate these significant research findings into human clinical studies.”

CTT1057 was designed as an ideal delivery vehicle and can be loaded with a variety of radionuclides and chemotherapies to specifically and safely guide imaging nuclides and therapies to PSMA-expressing prostate cancer. In 2014, CTT received a grant from the Washington state Life Sciences Discovery Fund to perform manufacturing and key preclinical studies for CTT1057. The current SBIR allows CTT to continue the manufacturing and file the Investigational New Drug Application for the human clinical trial in prostate cancer, set to commence in late 2015. CTT will work with contractors and collaborator Henry VanBrocklin, Ph.D., professor, Department of Radiology and Biomedical Imaging, and clinicians at University of California-San Francisco, to conduct initial clinical trials with 18F-labeled CTT1057.

VanBrocklin added: "We are eager to continue our collaboration with CTT to advance CTT1057 to human trials. We believe this important agent will improve the availability and efficacy of imaging for prostate cancer diagnosis, staging and treatment monitoring."

For more information: www.cancertargetedtechnology.com

Related Content

New ASNC SPECT Imaging Guideline Addresses Advances in Myocardial Perfusion Imaging
News | SPECT Imaging | June 21, 2018
The American Society of Nuclear Cardiology (ASNC) has published an update to its 2010 guidelines for single photon...
FDA Clears New Imaging Functionalities for Biograph mCT PET/CT Systems
Technology | PET-CT | June 21, 2018
Siemens Healthineers will announce U.S. Food and Drug Administration (FDA) clearance of four new system features for...
Technology | Focused Ultrasound Therapy | June 19, 2018
EDAP TMS SA has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Focal One device for...
New Prostate Cancer Radiotherapy Technique Aims to Preserve Sexual Function
News | Radiation Therapy | June 18, 2018
A multicenter clinical trial being led by UT Southwestern physicians is testing a technique for sparing nerve bundles...
Hitachi Medical Systems Europe Named Imaging Supplier for London Prostate Cancer Program
News | Prostate Cancer | June 14, 2018
Hitachi Medical Systems Europe has been awarded the contract to supply six ultrasound systems as part of the RAPID...
PET/CT Changes Care for 59 Percent of Suspected Recurrent Prostate Cancer Cases
News | Prostate Cancer | June 13, 2018
A recently presented investigational clinical trial evaluated the impact of 18F fluciclovine positron emission...
News | Brachytherapy Systems | June 07, 2018
IsoRay Inc. announced the upcoming release of its Build-Blu delivery system for real-time prostate brachytherapy.
Nuclear imaging scan showing very good tissue delineation. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Nuclear imaging scan showing very good tissue delineation. It offers crisp overall image quality and sharply delineates the muscle and fat planes, vertebral margins and end plates, billiary radicals, renal calyces, aortic wall and papillary muscles of the heart. Scan performed on a Biograph Vision positron emission tomography/computed tomography (PET-CT) system from Siemens Healthineers.

Technology | PET-CT | June 05, 2018
June 5, 2018 — The U.S.
Emerging Trends in Nuclear Medicine
Feature | Nuclear Imaging | June 04, 2018 | By Jeff Zagoudis
Nuclear imaging and its various modalities have long played an important role in the diagnosis and treatment of numer
News | Computed Tomography (CT) | May 21, 2018
The Istituto Oncologico Veneto (IOV) in Padua, Italy, has acquired MILabs’ latest-generation Versatile Emission...
Overlay Init